Fresenius Vamed - A Polyclinic in Ghana
Members of the Supervisory Board of Fresenius SE & Co. KGaA
Chairman of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2021
Current term of office: 2021 – 2025
Date of Birth: | March 19, 1955 |
Place of Birth: | Bensberg |
Nationality: | German |
Professional Experience
2002 - 2018 | DZ Bank AG
|
2000 - 2002 | Deutsche Bank AG, Frankfurt
Managing Director and Senior Credit Executive of the Corporates and Real Estate Division and CIB Corporate and Investment Bank |
1998 - 2000 | Deutsche Bank, Singapore
General Manager and Chief Country Officer |
1981 - 1998 | Deutsche Bank AG, Düsseldorf and Frankfurt
various positions within the Corporate and Investment Banking Division |
Education
1977 - 1981 | Universität Köln
Business Administration (Diplom-Kaufmann) |
1975 - 1977 | Deutsche Bank AG
Banking apprenticeship |
Membership of other statutory supervisory boards | |
Adolf Würth GmbH & Co. KG | |
Membership of comparable German or foreign supervisory bodies | |
None |
Medical Director and Spokesman of the Management Board Member of the Supervisory Board of Fresenius SE & Co. KGaA |
|
Date of Birth: | December 14, 1949 |
Place of Birth: | Munich |
Nationality: | German |
Professional Experience
since 2002 | University Hospital Carl Gustav Carus Dresden
Medical Director and Spokesman of the Management Board |
1999 - 2002 | Technical University of Dresden Dean of the Faculty of Medicine |
1997 - 1999 | Harvard Medical International Association Institution Dresden Director, founder and dean |
1994 - 1997 | Technical University of Dresden Appointment as a C4-Professor in anesthesiology and intensive care |
1989 - 1994 | University of Heidelberg
|
Education
1989 | University of Lübeck Habilitation in medicine (Prof. Dr. med.) |
1985 | LMU Munich Doctorate in medicine (Dr. med.) |
1971 - 1976 | LMU Munich Studies of medicine |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Full-time Works Council Member
Helios Vogtland-Klinikum Plauen GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2018
Current term of office: 2021 – 2025
Date of Birth: | October 1, 1958 |
Place of Birth: | Bad Elster |
Nationality: | German |
Professional Experience
since 09/2018 | Chairman of the Group Works Council Helios Kliniken GmbH |
since 2010 | Member of the European Works Council of Fresenius SE & Co. KGaA |
since 2006 | Helios Vogtland-Klinikum Full-time Works Council Member (Chairman) |
2003 - 2006 | Humaine Vogtland-Klinikum 50% Works Council Member (Chairman); 50% Degreed engineer, Department of biomedical engineering |
1990 - 2003 | Vogtland-Klinikum Plauen Degreed engineer
|
1985 - 1990 | Bezirkskrankenhaus Plauen Degreed engineer |
Education
1980 - 1985 | Ilmenau University of Technology Engineering degree in Technical Cybernetics and Biomedical Engineering |
Membership of other statutory supervisory boards | |
Helios Vogtland-Klinikum Plauen GmbH (Fresenius Group mandate) | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various Supervisory Boards
Deputy Chair of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2015
Current term of office: 2021 – 2025
Date of Birth: | December 23, 1954 |
Place of Birth: | Bielefeld |
Nationality: | German |
Professional Experience
2003 - 2015 | Allianz SE (formerly Allianz AG) Chairman of the Management Board |
1998 - 2003 | Allianz AG Member of the Management Board |
1988 - 1998 | Allianz Versicherungs-AG |
1983 - 1988 | Diekmann / Thieme GbR (publishing house) CEO |
Education
1973 - 1982 | University of Göttingen Studies in Law and Philosophy |
Membership of other statutory supervisory boards | |
Allianz SE1 (Chair) | |
Membership of comparable German or foreign supervisory bodies | |
None |
-
1 Stock listed company
Secretary of the Trade Union ver.di Vereinte Dienstleistungsgewerkschaft
Deputy Chair of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2020
Current term of office: 2021 – 2025
Date of Birth: | January 24, 1973 |
Place of BIrth: | Cottbus |
Nationality: | German |
Professional Experience
since 1991 | Trade Union Vereinte Dienstleistungsgewerkschaft ver.di
|
Education
1989 - 1991 | Lausitzer Braunkohle AG Apprenticeship as business management assistan |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Full-time Works Council Member
VAMED-KMB Krankenhausmanagement und Betriebsführungsges. m.b.H.
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2007
Current term of office: 2021 – 2025
Date of Birth: | July 21, 1959 |
Place of Birth: | Hof am Leithaberge |
Nationality: | Austrian |
Professional Experience
since 2008 | Member of the European Works Council of Fresenius SE & Co. KGaA
|
since 1991 | Member of the Group Works Council of VAMED AG
|
since 1991 | Full-time member of the Manual Workers‘ Works Council of VAMED-KMB Krankenhausmanagement und Betriebsführungsges. m.b.H. |
since 1986 | VAMED-KMB Krankenhausmanagement und Betriebsführungsges. m.b.H. |
1978 - 1986 | BBC High voltage installation technician |
Education
1974 - 1978 | BBC Apprenticeship as high voltage installation technician |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Full-time Works Council Member
Helios Kliniken Schwerin GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2016
Current term of office: 2021 – 2025
Date of Birth: | June 27, 1963 |
Place of Birth: | Schwerin |
Nationality: | German |
Professional Experience
since 2008 | Member of the European Works Council of Fresenius SE & Co. KGaA
|
since 2004 | Member of the Group Works Council Helios Kliniken GmbH |
since 1983 | Helios Kliniken Schwerin GmbH
|
Education
1980 - 1983 | Medical School Schwerin Graduation as hospital nurse |
Membership of other statutory supervisory boards | |
Helios Kliniken Schwerin GmbH (Fresenius Group mandate, Deputy Chair) | |
Membership of comparable German or foreign supervisory bodies | |
None |
Chief Medical Officer und Executive Vice President,
Head of Development, UCB S.A.
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2016
Current term of office: 2021 – 2025
Date of Birth: | November 17, 1960 |
Place of Birth: | Offenbach / Main |
Nationality: | German |
Professional Experience
2008 - today | UCB S.A. Chief Medical Officer and Executive Vice President Development |
2001 - 2009 | Schwarz Pharma AG Member of the Executive Board, Head of Research and Development |
2000 - 2001 | BASF Pharma Vice President Global Projects |
1992 - 2000 | Hoechst AG Various positions, last serving as Vice President Clinical Development |
Education
since 2000 | University of Frankfurt am Main Professor for internal medicine |
1985 | University of Frankfurt am Main Doctorate in medicine (Dr. med.) |
1979 - 1985 | University of Frankfurt am Main Studies of medicine |
Membership of other statutory supervisory boards | |
Evotec AG1 (Chair since 06/2021) | |
Membership of comparable German or foreign supervisory bodies | |
None |
-
1 Stock listed company
Full-time Works Council Member
Fresenius Kabi Deutschland GmbH
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2023
Current term of office: 2021 – 2025
Date of Birth: | May 18, 1969 |
Place of Birth: | Marburg |
Nationality: | German |
Professional Experience
since 2002 | Fresenius Kabi Deutschland GmbH, Standort Friedberg
|
since 2021 | Honorary Judge, Hessian Tax Court |
since 2017 | IHK-Examiner, IHK Frankfurt |
since 2015 | Honorary Judge, Labour Court |
2007 – 2018 | Laboratoy Manager, IPK-Laboratories |
2003 – 2007 | Quality Control Technician |
1992 – 2003 | Quality Control Laboratory Assistant |
Education / Academic Background
2021 | Specialist for Occupational Health Management, IHK |
2020 – 2021 | Certified Specialist for Data Protection and Data Security |
2018 | Project Manager, IHK |
1999 – 2001 | Training as Bachelor Professional of Management for Industry |
1985 – 1989 | Apprenticeship as Chemical Laboratory Technician |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Production staff member
Fresenius Kabi España S.A.U.
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2016
Current term of office: 2021 – 2025
Date of Birth: | January 29, 1974 |
Place of Birth: | Barcelona |
Nationality: | Spanish |
Professional Experience
since 2008 | Member of the European Works Council of Fresenius SE & Co. KGaA |
since 2004 | Member of the Works Council Fresenius Kabi España S.A.U. |
since 1998 | Fresenius Kabi AG |
Education
2016 | Seminar at ETUI (European Trade Union Institute): Current challenges for employee representatives in supervisory boards: How to deal with confidentiality rules and impact of European commercial law |
2015 | Seminar: Trade union cultures in the European Union Training for the European Works Council (EWC training center) Seminar: Occupational Health and Safety (Trainig center of CC.OO.) |
1990 - 1994 | Instituto Cristófol Ferrer, Secondary school |
Membership of other statutory supervisory boards | |
None | |
Membership of comparable German or foreign supervisory bodies | |
None |
Member of various Supervisory Boards
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2022
Current term of office: 2022 - 2025
Date of Birth: | February 28, 1961 |
Place of Birth: | Marl |
Nationality: | German |
Professional Experience
2012 - 2022 | Deutsche Beteiligungs AG, Frankfurt / Main Member of the Executive Board / Chief Financial Officer Responsible for finance and accounting, investor relations, legal and tax, portfolio valuation, risk management, internal audit, human resources, organization, IT |
2011 – 2012 | Kirche in Not, Königstein im Taunus Managing Director at the global headquarter of the organization |
1990 – 2011 | KPMG AG, Frankfurt / Main Last position: partner
|
1987 - 1990 | Winterhager Dr. Heintges Stützel Laubach GmbH, Wirtschaftsprüfungsgesellschaft, Düsseldorf Last position: Auditor and tax specalist |
Education
1995 | Appointment as auditor (2013 waiver of appointment) |
1992 | Appointment as tax advisor (2022 waiver of appointment) |
1980 - 1987 | Westfälische Wilhelms-Universität Münster
|
Membership of other statutory supervisory boards | |
Fresenius SE (Fresenius Group mandate) | |
Membership of comparable German or foreign supervisory bodies | |
None |
Former Member of the Managing Board Siemens Healthineers AG
Member of the Supervisory Board of Fresenius SE & Co. KGaA
Initial appointment: 2022
Current term of office: 2022– 2025
Date of Birth: | April 13, 1961 |
Place of Birth: | Stuttgart |
Nationality: | German |
Professional Experience
2019 – 2022 | Siemens Healthineers AG, Erlangen Member of the Managing Board Responsible for Imaging, Advanced Therapies, Technology & Innovation, Quality&Regulatory Affairs, Sustainability |
2018 – 2019 | Siemens Healthineers AG, Erlangen
President Diagnostic Imaging |
2015 – 2018 | Siemens AG, Healthcare Sector, Erlangen
SVP, General Manager of Business Line Magnetic Resonance |
2014 – 2015 | Beckmann-Coulter – A Danaher Company, Miami (USA) SVP, Head of Business Unit Hematology and Urinalysis |
2012 – 2014 | Siemens AG, Healthcare Sector, Knoxville (USA) CEO PETNET Solutions (Radiopharmaceuticals) |
1998 – 2012 | Siemens AG, Healthcare Sector, Erlangen Various leading positions: Marketing, R & D |
1994 – 1998 | University Tübingen Resident Physician Surgery |
1993 - 1994 | University Frankfurt am Main Resident Physisian Internal Medicine, Nuclear Medicine |
Education
1995 | University Frankfurt am Main
Doctor of Medicine, M.D. (Dr.) |
1985 – 1992 | University Frankfurt am Main Studies in Medicine |
Membership of other statutory supervisory boards | |
Gerresheimer AG | |
Membership of comparable German or foreign supervisory bodies | |
None |
Committees of the Supervisory Board of Fresenius SE & Co. KGaA
Wolfgang Kirsch (Chair)
Michael Diekmann
Susanne Zeidler
Susanne Zeidler (Chair)
Bernd Behlert
Grit Genster
Wolfgang Kirsch
Dr. Christoph Zindel
Dr. Dieter Schenk (Chair)
Michael Diekmann
Wolfgang Kirsch
Susanne Zeidler
The committee consists equally of two members each of the Supervisory Board of Fresenius SE & Co. KGaA and of Fresenius Management SE.
Additional information on the Supervisory Board of Fresenius SE & Co. KGaA
Rules of Procedure
CVs of the Supervisory Board members
Meeting participation by individual
Members of the Supervisory Board of Fresenius Management SE
Chairman of the Supervisory Board of Fresenius SE & Co. KGaA
Former Chief Executive Officer of Deutsche Post DHL Group
Member of various Supervisory Boards
Member of various Supervisory Boards
Deputy Chairman
Member of supervisory bodies
Member of supervisory bodies
Contact
As a global healthcare Group, sustainable success in our business is the key to providing high-quality yet affordable healthcare over the long term. Compliance ensures this sustainable growth, determines our corporate culture, and is an integral part of our day-to-day work. We at Fresenius are fully committed to compliance. The wellbeing of our patients is our top priority in everything we do. Our patients rely on us. Therefore, we are committed to the highest quality of our products and services, integrity in dealing with our partners, responsible conduct, and reliability. That is what we stand for. That is what is important to us.
At Fresenius, integrity and ethical conduct govern the activities of our operations.
Guided by our comprehensive Code of Conduct, we are fully committed to compliance with laws, internal guidelines, and ethical standards.
Our Code, endorsed by the Group Management Board, serves as a universal framework for behavior across the Fresenius Group, applying to all employees, including management at every level. It encompasses principles aligned with recognized international regulations and is customized within each business segment to reflect its unique characteristics. Integral to our employment contracts, the Code ensures all our employees uphold the applicable standards of conduct. In addition, the business segments implemented their own Codes of Conduct which are adapted to the individual characteristics of each business segment. Furthermore, our commitment extends to regulating political activities, ensuring our employees adhere to both our ethical framework and legal standards.
Through mandatory training, including aspects of human rights, we ensure every employee at Fresenius is committed to the principles laid out in our Code of Conduct.
At Fresenius, we uphold the applicable standards not only within our operations but across our supply chain. Our revised Code of Conduct for Business Partners, enriched with human rights considerations and aligned with the German Act on Corporate Due Diligence Obligations in Supply Chains (LkSG), sets clear expectations for ethical conduct towards business partners and suppliers. This Code mandates compliance with all applicable laws and explicitly prohibits corruption and bribery, aligning with both national and international anti-corruption laws. Our commitment extends to ensuring transparency in interactions with healthcare professionals.
Prior to initiating any business relationship, we inform our partners about these requirements and conduct risk-based due diligence. Our Codes of Conduct are publicly accessible, reflecting our transparency and commitment to ethical business practices.
Furthermore, our commitment to human rights extends beyond our own operations. Through our Human Rights Program, we select suppliers and business partners who respect human rights within their value chains.
This commitment reflects our values and the care we extend to our patients and over 190,000 employees worldwide.
At Fresenius, our Compliance Management System (CMS) is aligned with the activity of our business segments, designed to proactively prevent corruption and bribery within our business environment. Tailored to the needs of our business segments, our CMS aspire to integrate a deep understanding of compliance into our daily operations.
Our system is built risk-oriented on the pillars of prevention, detection, and response, aiming to embed a living compliance culture across all levels of our organization. This culture is not static but evolves through continuous improvement and active exchange of best practices across our segments. The business segments develop operational goals and measures on an annual basis to continuously strengthen the compliance management system.
The Group function Risk & Integrity advises the corporate functions, sets minimum standards for the compliance management system Group-wide, and manages the Group-wide compliance reporting.
The Risk Steering Committee (RSC) – under the management of the ESG Board member – discusses internal and external developments regarding the risk management and internal control system as an advisory body. This includes, for example, developments relevant for the compliance management system.
The Group Chief Compliance Officer, the Chief Compliance Officers, or Heads of Compliance of each business segment and the Head of Group Reporting & Monitoring form the Group Compliance Management Team (GCMT). This management team meets on a monthly basis and sets the governance standards for compliance at Fresenius and supports the effective implementation of the compliance management system. The GCMT regularly examines the results of the compliance risk analysis, the compliance figures, the further development of the compliance management system and the results of monitoring measures.
The design and implementation of our compliance management system is based on international regulations and guidelines, such as the ISO standards on the setup of compliance management systems and applicable audit standards of the Institute of Public Auditors in Germany, Incorporated Association IDW (PS 980). When implementing measures, we take into account the respective national or international legal frameworks. In addition, a law firm reviewed the design of the Corporate CMS and concluded that it is organizationally effectively anchored and programmatically appropriately designed.
Post-acquisition, we quickly integrate new entities into our compliance framework, ensuring our standards are uniformly applied.
At Fresenius, upholding our ethical standards and compliance is central to our business. We empower our employees and external stakeholders to voice concerns about potential misconduct, including violations of laws, regulations, or our internal guidelines. Our comprehensive and confidential reporting system is accessible globally, supporting submissions in over 30 languages through various channels. Reports can be made by name or anonymously at any time of the day.
Incoming reports are treated confidentially and are taken seriously. Each report is carefully evaluated for its plausibility and potential impact. Our independent employees of the Group Case Management and Investigation Office (Group CMIO) ensure thorough comprehensive investigations, involving both internal and external expertise where necessary and in strict compliance with the “need to know” principle.
Actions are promptly taken by the responsible management in collaboration with the Group CMIO, guided by the severity and nature of the misconduct.
Our approach not only addresses immediate concerns but also strengthens our processes to prevent future issues.
Measures are implemented in a timely manner by the responsible management in close cooperation with the Group CMIO. Depending on the type and severity of the misconduct, disciplinary sanctions or remedies under civil or criminal law may be imposed. After completion of the investigation, we use the results of internal reviews and reports to review our business processes. We implement corrective or improvement measures where necessary to prevent similar misconduct in the future.
Compliance cases are evaluated based on the Group-wide policies as well as on those of the business segments, which comply with the Group-wide policies.
For anyone wishing to report a concern or seek advice, the Group CMIO team is easily reachable:
Online Reporting Platform: https://freseniusgroup.ethicspoint.com
Phone number: +49 (0) 800 181 1338*
The whistleblowing system can be used for reports concerning Fresenius Management SE, Fresenius SE & Co. KGaA, Fresenius Digital Technology GmbH and other Fresenius Corporate entities. Please address reports for Fresenius Kabi, Fresenius Helios, or Fresenius Vamed to the relevant business segment.
Fresenius Group is not responsible for receiving or processing reports concerning Fresenius Medical Care. Fresenius Medical Care reporting channels are published on the following website: Compliance Overview | Fresenius Medical Care
These channels ensure that reaching out is straightforward, secure, and supportive for all.
Only acting in an exemplary fashion enables us to maintain our integrity and the trust of our colleagues and partners. Every one of us is responsible for our personal behavior.
Thank you for your support and commitment to compliance at Fresenius.
* The prices of your mobile or landline contract apply
The tax strategy of Fresenius Group is aligned with our core values: Wellbeing of patients, Quality, Integrity, Responsibility and Reliability.
The tax compliance objectives are aimed at safeguarding compliance with all tax laws and reporting obligations and enhancing shareholder value based on the following principles:
1. We strive to maintain a culture that ensures that all people in our organization are aware that observing rules and the correct handling of tax matters is essential to the Fresenius Group.
2. The Fresenius Corporate Tax department and the other segment tax functions in the group are creating awareness of tax compliance in the Fresenius Group which is implemented in the Code of Conduct. This includes providing appropriate information and training to employees who perform tax-related tasks. The respective rules and procedures of this tax compliance objectives have been adopted by the Management Board.
3. We have to ensure that all applicable tax laws and reporting obligations are observed in a comprehensive and timely manner and that tax affairs are managed responsibly and transparently. We maintain an internal control system that meets existing standards and ensures that we comply with the tax and reporting obligations in all jurisdictions where we do our business. Appropriate processes and efficient controls shall safeguard that tax risks are identified, systematically recorded and assessed considering their probability of occurrence and potential financial exposure and reported in our external financial reporting.
4. Fresenius Corporate Tax department acts as a central point of contact for all Group tax functions, providing support and advice. Together they act as partners of the operating business units rendering attention, support and advice for transactions as well as for day-to-day business. In addition, the Fresenius Corporate Tax department also performs in whole or in part the tax function for some business segments.
5. Complying with applicable tax laws and upholding our reputation with governmental authorities and the public, we support the relevant business processes as well as sustainable growth of shareholder value with efficient tax planning. We don´t engage in tax arrangements without business purpose or commercial rationale. We routinely seek external professional guidance to reduce uncertainty when required.
6. Intercompany transfer pricing policies are set in accordance with arm’s length’s principles following international standards, i.e. taxes have to be paid on profits according to where value is created.
7. Communication and cooperation regarding tax issues is organized in a way that safeguards that all information is managed in a timely and appropriate manner. Tax is part of the internal control system and Risk Reporting. The FSE Group Chief Financial Officer (“CFO”) will be informed about all relevant tax matters and the development of tax risks. The Fresenius Corporate Tax department reports regularly to the CFO. The responsible CFOs ensures adequate resources for the tax function.
8. We support a cooperative, honest and respectful approach with tax authorities and other public bodies which we consider essential for efficient tax compliance and risk management.
9. We support initiatives such as the initiatives of the Organization for Economic Cooperation and Development (“OECD”) regarding Cooperative Compliance (whereby tax authorities and taxpayers benefit equally from more transparency) and Base Erosion and Profit Shifting (“BEPS”).
10. We continuously monitor changes in tax laws and practice. We recognize the importance of participating in discussions on the development of new tax legislation either directly or through the respective interest groups.
11. We are committed to employing and retaining excellent tax professionals long-term. We continuously work on our employer attractiveness, taking into account personal skills and providing a professional environment for personal development.
![](/sites/default/files/2021-10/770px_Blutbeutel.jpg)
For blood donation and component processing, Fresenius Kabi offers medical devices. These include cell separators (apheresis systems), autotransfusion devices, blood bag and filter systems as well as related blood processing equipment. Component processing consists of the separation and collection of certain blood cells.
Blood Cell Separator
The Fresenius cell separator has three areas of application:
- Donate blood cells: obtaining cells from the blood of a donor for transfusion, for example for treating coagulation dysfunctions or leukemia patients
- Remove cancer cells: removing diseased cells or blood plasma from the blood of a patient with leukemia or an autoimmune disease, i. e., in patients with disorders where the body produces defense substances against its own cells
- Collect a patient’s cells: collecting cells from a patient's own blood for re-infusion, for example prior to operation.
A cell separator is primarily used to collect blood platelets or thrombocytes. While red blood cells mainly transport oxygen and other blood cells ward off pathogens, thrombocytes play an important role in blood clotting. Patients with too few thrombocytes suffer from an inability of the blood to coagulate properly. Injuries can lead to potentially dangerous bleeding. One example of the cause of thrombocyte deficiency is cancer therapy. Doctors infuse patients with healthy donor thrombocytes following treatment.
Thrombocytes are obtained most effectively with a blood cell separator. The machine, which works like a centrifuge, gently separates thrombocytes from the other blood components. Components that are not needed are immediately returned to the donor. Because only the thrombocytes are taken, which regenerate much quicker than red blood cells, a donor may donate much more frequently than in regular whole-blood donations. The cell separator also allows a much larger number of thrombocytes to be collected per donation than in whole blood. All patients who require a large number of thrombocytes can benefit double from the procedure – regular transfusions include thrombocytes from several sources but a blood cell separator can reduce the number of donors needed per transfusion. This allows a doctor to select thrombocytes from the most appropriate donors. This is important because the efficacy of the thrombocytes improves when the blood groups of donors and recipients match.
A cell separator can separate thrombocytes from other blood cells; it can also support the treatment of leukemia patients by removing diseased cells directly from the blood. Since leukemic cancer cells quickly reproduce, this procedure cannot heal a patient. But it relieves the strain on the kidneys by considerably lowering the number of destroyed cancer cells that must be removed from the blood following treatment.
Although rarely used, another application of the blood cell separator is quickly gaining in importance. Doctors can use the device to remove stem cells from the blood of a cancer patient. Through pre-treatment bone marrow stem cells start to reproduce and partially move into the blood stream. These stem cells can be collected almost like platelets. This way surgery to obtain stem cells directly from bone marrow can be avoided.
The treatment subsequently used to combat cancer cells damage the stem cells from which all other blood cells are made. If the patient receives healthy stem cells after chemotherapy, healthy blood cells can develop quicker, for example the platelets that are important for hemostasis and coagulation.
Blood bag systems
Blood bag systems are the foundation for worldwide blood supply by "classical" blood donation. More than 90 percent of all blood donations are processed in these systems that consist of up to six different bags with variable functions.
A combination of bags with venous cannulae and integrated needle protection, pre-donation sampling pouches and different filtration devices form the basis for highly professional whole blood collection systems. They allow producing different blood component preparations according to national and international standards. Blood donation and processing with these systems is supplemented by other devices such as automated scales and blood separators, sterile docking systems and sealers to name a few.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
![](/sites/default/files/2023-07/770px_Rehabilitation%2C%20Pflege%20und%20Gesundheitstourismus.png)
Fresenius Vamed is a leading provider of rehabilitation services and operates its own care facilities in Europe.
VAMED Vitality World builds a bridge between preventive medicine and health tourism. In Austria, Fresenius Vamed is the market leader with more than 3 million visitors per year to nine spas and health resorts
Rehabilitation
With its rehabilitation facilities, Fresenius Vamed helps patients to minimize restrictions caused by illness or accident as far as possible. VAMED relies on a combination of modern medicine, personalized and individually tailored rehabilitation goals, and personal attention. Thus, even after severe illnesses, patients are enabled to achieve the best possible improvement of their functions to increase their self-activity and participation in all areas of life as far as possible.
Fresenius Vamed is the leading private rehabilitation provider in Austria, Germany, Switzerland, and the Czech Republic with more than 8,200 beds.
In addition to the well-established inpatient rehabilitation clinics, the offer of outpatient rehabilitation options close to the patient's home is increasingly gaining in importance. VAMED has significantly extended this offer, hybrid and telerehabilitation are also being expanded. Digital rehabilitation offers the possibility to treat patients comprehensively, continuously, and effectively also between physical visits to the doctor or clinic.
Care
Another important area of post-acute care is nursing care, with the claim to offer the residents of the facilities a home and to care for them in their everyday life with full commitment and medical as well as nursing competence. VAMED oversees care facilities in Austria, Germany, and the Czech Republic.
Health Tourism
VAMED Vitality World's spa and health resorts offer medical-therapeutic methods and extensive treatments to improve guests' physical and mental well-being. Years of experience in the health sector have enabled VAMED to build a bridge between preventive medicine and health tourism.
Since 1995, the international health care group VAMED has been active in the field of thermal spas and wellness. Today, under the umbrella brand VAMED Vitality World, it operates eight of the most popular thermal and health resorts in Austria and is market leader with more than 3 million visitors per year.
The concept focuses on the essentials: on people. Guests benefit from this expertise because well-being is the focus. This begins with the choice of location for the facilities, which are embedded in unique landscapes in the most beautiful regions of Austria. Each house impresses with its architecture and is surrounded by generous thermal landscapes and sauna worlds. The highest quality also applies to the health, wellness and beauty treatments, healthy regional and seasonal cuisine, and a wide range of sports and exercise programs - all of which turn a stay into a holistic recreational experience.
Contact
VAMED Aktiengesellschaft
Sterngasse 5
1230 Vienna
Austria
+43 1 601 27-0
office@vamed.com
![](/sites/default/files/2021-10/770px_HPC_Diagnostik_21x14_print_2N2A1382_jiw.jpg)
Comprehensive patient care begins with prevention. Fresenius Helios' occupational healthcare centers offer a wide range of workplace prevention services. In addition, the Helios Prevention Center (HPC) of Fresenius Helios offers programs for individual prevention and company health management in the form of checkups and health coaching at numerous locations around Germany.
Occupational Healthcare
The aim of effective occupational healthcare is to maintain and promote health, prevent harmful influences resulting from working life, detect illnesses and damage to health at an early stage, as well as reintegrate employees into the workplace after a longer period of absence due to illness.
In Germany, Helios offers fully comprehensive occupational medical care with a fixed, permanent contact person at 17 occupational healthcare centers. This covers everything from legally required examinations, health protection and promotion to risk assessments and recommendations for optimal workplace design.
Spain's leading occupational risk prevention companies Fraterprevención, MC Prevención, Premap and Unipresalud complement the Quirónsalud network, with more than 150 centers throughout Spain and a presence in Latin America and the Middle East.
Helios Prevention Center (HPC)
A check-up at the Helios Prevention Center provides an accurate picture of one's own state of health. Our participants at one of our six locations benefit from short waiting times, short distances and holistic lifestyle advice.
The HPC qualifies participants to handle health issues with confidence and enables them to achieve a performance grade that can function as a model. Health conscious and competent leadership can act as a beacon to bind together and motivate employees. HPC views itself as a partner to companies that want to actively promote the health of their employees. From a one-day checkup at a Helios clinic to health workshops lasting several days at beautifully situated resorts – our modular program combines Helios quality with the ambience of exclusive hotels. Studies show occupational healthcare measures generate outstanding cost-benefit ratios.
Contact
Helios Prevention Center
Service-Hotline: 0800-633 49 46
info@helios-preventioncenter.de
Related Links
Fresenius Helios![](/sites/default/files/2021-10/770px_Vamed_Management.jpg)
Fresenius Vamed is a leading global provider of services for hospitals and other healthcare facilities. Its portfolio ranges from project development and planning to the total operational management of healthcare facilities and providing services to patients. The services are aimed at various areas of healthcare, ranging from prevention to acute care, rehabilitation, and nursing.
Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed more than 1,000 healthcare projects in 101 countries on five continents since the company’s founding in 1982.
VAMED Value Chain
Project business:
- Project development
- Planning
- Project management and construction
Service business:
- Services (technical, commercial, infrastructural)
- Operational management (technical Management, total operational management)
The project business comprises the consulting, project development, planning, turnkey construction, and financing management of projects. VAMED responds flexibly to the local needs of clients, providing custom-tailored solutions all from one source. The company also carries out projects in cooperation with partners. Among public clients there is growing interest in public-private partnership (PPP) models. With 25 of these models, VAMED is a pioneer in this market segment.
VAMED offers a full range of facility management services for healthcare facilities. Modular in design, the company's service offering encompasses every aspect of technical, commercial, and infrastructural facility management. This ranges from building and equipment maintenance, medical technology management, and technical management through to the operational management. Its integrated portfolio of services is aimed at the optimal operation of a healthcare facility. VAMED was responsible for the total operational management of about 100 healthcare facilities on five continents with more about 18,000 beds. Worldwide, VAMED provides technical operation services to more than 840 hospitals with about 227,000 beds.
VAMED Vitality World’s thermal spa and wellness resorts have succeeded in bridging the gap between preventive medicine and healthcare tourism. With more than 3 million visitors annually in nine thermal spas and wellness resorts, VAMED is the market leader in Austria.
Vamed belongs to Fresenius SE & Co. KGaA healthcare group with a stake of about 77 percent and is one of the two Investment Companies of Fresenius.
Contact
VAMED Aktiengesellschaft
Sterngasse 5
1230 Vienna
Austria
office@vamed.com
+43 1 601 27-0
![](/sites/default/files/2023-06/Berlin_Buch_Haupteingang_20x30_print_2N2A6580.jpg)
Helios is Europe's leading private health care provider, with 127,000 employees. Together with Quirónsalud in Spain and Latin America, Helios Group in Germany is part of the holding Helios Health. Every year about 26 million patients choose Helios for medical treatment. In 2023, the company’s sales totaled more than €12 billion
Helios Germany operates more than 80 hospitals, about 230 outpatient care centers with 600 accredited doctor's licenses, six prevention centers and 27 occupational medicine centers. Helios treats approximately 5.5 million patients annually, of whom 4 million are outpatients. Since its beginnings, Helios has focused on measurable, high medical quality as well as data transparency and is better than the German average in 88 per cent of the quality targets. With more than 78,000 employees, Helios generated sales of €7.3 billion in 2023. Helios Germany is headquartered in Berlin.
Quirónsalud operates 58 hospitals, including eight in Latin America, 100 outpatient centers and around 300 occupational risk prevention centers, and treats approximately 20 million patients annually, of whom 19 million are outpatients. Quirónsalud has more than 49,000 employees and generated sales of €4.8 billion in 2023.
Helios Health is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Contact
Helios Kliniken GmbH
Friedrichstr. 136
10117 Berlin
Germany
T +49 30 521 321-0
![](/sites/default/files/2021-10/Factsheet4.jpg)
Fresenius is one of the top 40 companies in Germany in terms of market capitalization and is included in Germany's leading index, the DAX. We are also listed in the STOXX Europe 600 Health Care, the FTSEurofirst 300 and the DAXsector Pharma & Healthcare indices.
Fresenius ordinary shares are traded on the stock exchanges in Frankfurt, Düsseldorf and Munich.
At the end of July 2022, Fresenius SE & Co. KGaA's capital stock was 563,237,277 ordinary shares. The shares are notional no-par-value shares. Each share represents €1.00 of the capital stock.
Basic Share information
Ordinary share | |
---|---|
Securities identification no. | 578 560 |
Ticker symbol | FRE |
ISIN | DE0005785604 |
Bloomberg symbol | FRE GR |
Reuters symbol | FREG.de |
Main trading location | Frankfurt/Xetra |
Paying agent | Deutsche Bank AG, Taunusanlage 12, 60325 Frankfurt am Main, Germany |
Key data
2023 | 2022 | 2021 | |
---|---|---|---|
Numbers of shares | 563,237,277 | 563,237,277 | 558,502,143 |
Stock exchange quotation1 in € | |||
High | 31.11 | 37.88 | 47.44 |
Low | 23.46 | 20.04 | 33.35 |
Year-end quotation | 28.07 | 26.25 | 35.40 |
Market capitalization2 in million € | 15,810 | 14,785 | 19,771 |
Total dividend distribution in million € | - | 518 | 514 |
Dividend per share in € | - | 0.92 | 0.92 |
Earnings per share in €3 | 2.67 | 3.08 | 3.35 |
-
- 1 Xetra closing price on the Frankfurt Stock Exchange
- 2 Total number of ordinary shares multiplied by the respective Xetra year-end quotation on the Frankfurt Stock Exchange
- 3 Net income attributable to shareholders of Fresenius SE & Co. KGaA; before special items
Contact
![](/sites/default/files/2022-01/Florian_Feick.jpg)
Vice President Investor Relations
Deputy Head of Investor Relations
T: +49 (0) 6172 608-5167
florian.feick@fresenius.com
Related Links
Interactive ToolEvent
June 05, 2024 | London, UK
![](/sites/default/files/2024-02/370px_Capital-Markets-Day-Visual_Helios.png)
![](/sites/default/files/2021-10/770px_Klinische_Ernaehrung.jpg)
Nutrition is a topic which is all around us, day by day. While we often talk about obesity and weight loss diets we actually overlook that the opposite, meaning mal- or undernutrition, can be as detrimental. We talk about malnutrition when our body is not provided with sufficient energy and nutrients over several days. These nutrients, for example protein, carbohydrates, fats, vitamins and minerals, are necessary to ensure all essential functions of the body.
When our nutritional status is not optimal our body will get weaker in its reaction towards challenges, such as a disease, a cold or an infection. Improving our nutritional status will therefore support and protect our body.
Enteral Nutrition
Every normal form of nutrition is actually enteral. The word, which comes from the Greek “enteron,” or intestines, means, “using the gastrointestinal tract.” Enteral nutrition therapies are designed for patients who cannot nourish themselves sufficiently but still have an adequate digestive function. It is therefore ideal for patients who experience problems chewing or swallowing, loss of appetite, suffer from neurological or gastro-intestinal diseases, or are unconscious. Enteral nutrition is administered via sip feeds or also tube feeds.
If you are not able to eat enough, sip feed nutrition can help to make up for this deficit. Sip feed nutrition can be taken by mouth, swallowed and digested like normal food. It is flavorful, liquid food and contains all nutrients such as carbohydrates, fats and fiber as well as vitamins, minerals and trace elements.
Sip feed nutrition is balanced. It contains all the nutrients required by a person. Therefore, it can be drunk or eaten in addition to normal food but is also suitable as a sole source of nutrition.
Tube feed nutrition can help you to meet your nutritional needs in times when you are not able to eat enough.
Tube feeding is a procedure used for administering liquid nutrition directly into the stomach or small intestine. To do this, a thin tube (probe) is inserted either through the nose (nasal probe) or through the abdomen into the stomach.
Parenteral Nutrition
Patients who are given Fresenius Kabi infusion solutions receive all the components of balanced nutrition: carbohydrates, amino acids and fats as well as minerals, vitamins and trace elements. The composition of these nutritional solutions can be precisely balanced to feed a patient for any period of time.
Parenteral nutrition is necessary when the stomach or intestine – for instance due to an illness or operation – can no longer perform their tasks. A doctor may also decide that a patient should receive parenteral nutrition prior to an operation or during lengthy examinations when he or she is not allowed to eat. In intravenous nutrition, all key nutrients enter the bloodstream as molecular components. A patient can rely on parenterally given nutrients for a long period of time.
There are a number of liquids with a variety of compositions that can be used for parenteral nutrition therapy either on their own or as a mixture. When deciding on the best nutritional therapy, the general condition of the patient plays an important role, as well as a patient’s age and weight. There are also solutions for patients with kidney or liver disease that contain a special composition of amino acids. Fresenius Kabi offers amino acids and carbohydrates as single components but also as a combination that contains both nutritional elements. Three-chamber bags contain all three important nutrients including fats.
Carbohydrates are the most important source of energy
Carbohydrates are the most important source of energy in parenteral nutrition. Often, glucose alone is sufficient. Glucose is a "universal fuel" that can be utilized by all the body’s cells, making it a standard nutrient for parenteral nutrition. Doctors can choose between solutions with different glucose concentrations. Combined solutions also contain other nutritional components besides carbohydrates.
Amino acids are essential for parenteral nutrition
Amino acids are the smallest components of proteins that perform many tasks in the body. Every organ requires proteins for its structure and function. Proteins transport, act as messengers, fight germs or control and create vital metabolic reactions. They are also important building blocks for muscles, hair and finger nails, for example.
All proteins consist of different amino acids. Therefore, amino acids are also indispensable for parenteral nutrition. Fresenius Kabi offers solutions containing amino acids in an ideal composition that the body can use to generate the required proteins.
Fats contain lots of energy and essential fatty acids
Fats contain not only a lot of energy, but also important fatty acids that the body itself cannot produce. These essential fatty acids help build up cell membranes and transmitters that regulate the metabolism.
Patients who are fed parenterally receive the fats as microscopic droplets that are suspended in a liquid known as emulsion. When this emulsion is infused into the blood stream, the tiny droplets disperse in the blood and can be absorbed by the body's cells. Fat emulsions help doctors to provide critically-ill patients with quickly-available energy while offering a reliable source of essential fatty acids.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com
![](/sites/default/files/2021-10/770px_Friedberg.jpg)
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.
Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition portfolio includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, Fresenius Kabi offers vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.
Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.
Fresenius Kabi employs over 40,000 people worldwide. In 2023 the company reported sales of more than €8 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA healthcare group and one of the two Operating Companies of Fresenius.
Contact
Fresenius Kabi AG
Else-Kröner-Str. 1
61352 Bad Homburg
Germany
T: +49 6172 686-0
communication@fresenius-kabi.com